Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q8TAF8

UPID:
LHPL5_HUMAN

ALTERNATIVE NAMES:
Lipoma HMGIC fusion partner-like 5 protein; Tetraspan membrane protein of hair cell stereocilia

ALTERNATIVE UPACC:
Q8TAF8; B3KX66

BACKGROUND:
The LHFPL tetraspan subfamily member 5 protein, alternatively known as the Tetraspan membrane protein of hair cell stereocilia, is integral to the hair cell's mechanotransduction machinery in the inner ear. It ensures the proper functioning of the transducer channel, essential for hearing.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of LHFPL tetraspan subfamily member 5 protein could open doors to potential therapeutic strategies for combating sensorineural hearing loss, particularly in conditions like Deafness, autosomal recessive, 67.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.